PAD Clinical Trials 2024

What are the top hospitals conducting pad research?

Peripheral artery disease (PAD) affects millions of people worldwide, causing narrowing or blockage in the blood vessels that supply the legs and feet. In our quest for innovative treatments, several leading hospitals have emerged as beacons of hope in the field of PAD clinical trials. Boston’s Massachusetts General Hospital takes a prominent role with six active trials focused on PAD and a cumulative record of 11 studies conducted since their first recorded trial back in 2005. Similarly, Northwestern University in Chicago stands tall with six ongoing PAD trials and an impressive total of 17 previously completed investigations since they embarked on this journey in 2006.

Making strides alongside these renowned institutions is the University of Chicago, which currently conducts five active clinical trials for patients suffering from PAD. Since initiating their pioneering trial in 2001, they have amassed eight additional studies aimed at finding breakthroughs to improve outcomes for those affected by this condition. Meanwhile, at the University of Minnesota located in Minneapolis, researchers are pursuing five ongoing PAD trials while building upon their experience from eleven already completed investigations since entering this realm back in 2009.

Lastly but certainly not least, we turn our attention to Charlottesville's esteemed University of Virginia where four current clinical trials addressing peripheral artery disease offer promise for cutting-edge advancements. Although relatively recent entrants into this area with their initial recorded trial occurring only ten years ago -in2010-, they have already contributed nine valuable studies towards expanding our understanding and treatment options when it comes to alleviating suffering caused by narrowed leg arteries.

With each research endeavor undertaken by these top hospitals across various locations nationwide comes renewed hope for individuals grappling with PAD—a collective effort dedicated to improving quality-of-life outcomes through groundbreaking discoveries. The passion and commitment displayed within these medical institutions pave the way toward a future where new treatments hold potential to transform countless lives impacted by peripheral artery disease

Which are the best cities for pad clinical trials?

In the realm of clinical trials for peripheral arterial disease (PAD), several cities emerge as hotspots for cutting-edge research. Chicago, Illinois leads the pack with 16 active trials investigating interventions like supervised treadmill exercise combined with nitrate-rich beetroot juice and Metformin. Boston, Massachusetts follows closely behind with 11 ongoing studies focused on innovative technologies such as the LimFlow System and Surmodics SurVeil DCB. New york, New York also shines in this field with 10 active trials exploring treatments like Intravascular Lithotripsy and PQ Bypass System. Raleigh, North carolina and Gainesville, Florida round out the list with their own contributions to PAD research. These cities offer individuals affected by PAD access to promising clinical trials that may advance our understanding of this condition and pave the way for improved treatment options.

Which are the top treatments for pad being explored in clinical trials?

Clinical trials for peripheral artery disease (PAD) are exploring various treatments that show promise in combating this condition. The PQ Bypass System, introduced in 2017, is currently being evaluated in two active trials focused on PAD. Additionally, exercise has emerged as a potential treatment option and is the subject of two ongoing clinical trials. With a total of eleven all-time PAD trials since its first listing in 2003, exercise remains an area of interest for researchers seeking effective interventions against this debilitating disease.

What are the most recent clinical trials for pad?

Recent clinical trials have shed light on potential breakthroughs in the treatment of peripheral artery disease (PAD). One notable study investigated the efficacy of supervised treadmill exercise combined with nitrate-rich beetroot juice, offering a novel approach to managing this condition. Another trial focused on the use of liposomal bupivacaine as a promising intervention for PAD patients. Additionally, carnosine has shown promise in early-stage research, indicating its potential benefits for individuals affected by PAD. Moreover, heat therapy and rivaroxaban 2.5 mg oral tablet have also been explored as possible avenues for improving outcomes in patients diagnosed with PAD. These ongoing studies hold great promise for enhancing treatments and quality of life among those living with this debilitating vascular disorder.

What pad clinical trials were recently completed?

Recently completed clinical trials have made significant progress in the field of peripheral artery disease (PAD). In May 2020, Alucent Biomedical concluded a trial investigating the potential of NVS Therapy to treat this condition. Around the same time, Florida State University successfully completed a trial exploring the use of Creatine monohydrate as a therapy for PAD. Although slightly older, an additional noteworthy study was conducted by the University of Virginia and finished in July 2017, which examined Alirocumab's efficacy for PAD treatment. These advancements underscore ongoing efforts to find innovative solutions that can improve outcomes for individuals battling PAD.